ORIC Pharmaceuticals Q4 loss narrows

Reuters02-24

ORIC Pharmaceuticals Q4 loss narrows

Overview

Oncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last year
Company raised $264 mln, extending cash runway into 2H 2028
Significant clinical advancements in rinzimetostat and enozertinib reported

Outlook

ORIC expects rinzimetostat dose optimization data in Q1 2026
Company plans to initiate Phase 3 trial for rinzimetostat in 1H 2026
ORIC anticipates enozertinib monotherapy data in 2H 2026

Result Drivers

R&D EXPENSES - Reduced to $25.9 mln from $32 mln due to lower rinzimetostat drug manufacturing costs and lower costs from discontinued programs
CASH RUNWAY EXTENSION - Company raised $264 mln, extending cash runway into 2H 2028

Company press release: ID:nGNX4wfBSH

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$30.51 mln
Q4 Income from Operations		-$34.55 mln
Q4 Operating Expenses		$34.55 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 98% above its February 20 closing price of $11.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613308057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 05:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613308057","market":"us","top_or_hot":-1,"title":"ORIC Pharmaceuticals Q4 loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ORIC Pharmaceuticals Q4 loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Oncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last year</p></li><li><p>Company raised $264 mln, extending cash runway into 2H 2028</p></li><li><p>Significant clinical advancements in rinzimetostat and enozertinib reported</p></li></ul><p><span>Outlook</span></p><ul><li><p>ORIC expects rinzimetostat dose optimization data in Q1 2026</p></li><li><p>Company plans to initiate Phase 3 trial for rinzimetostat in 1H 2026</p></li><li><p>ORIC anticipates enozertinib monotherapy data in 2H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Reduced to $25.9 mln from $32 mln due to lower rinzimetostat drug manufacturing costs and lower costs from discontinued programs</p></li><li><p>CASH RUNWAY EXTENSION - Company raised $264 mln, extending cash runway into 2H 2028</p></li></ul><p>Company press release: <span>ID:nGNX4wfBSH</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$30.51 mln</p></td><td></td></tr><tr><td><p>Q4 Income from Operations</p></td><td></td><td><p>-$34.55 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$34.55 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 98% above its February 20 closing price of $11.11</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORIC Pharmaceuticals Q4 loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORIC Pharmaceuticals Q4 loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 05:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ORIC Pharmaceuticals Q4 loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Oncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last year</p></li><li><p>Company raised $264 mln, extending cash runway into 2H 2028</p></li><li><p>Significant clinical advancements in rinzimetostat and enozertinib reported</p></li></ul><p><span>Outlook</span></p><ul><li><p>ORIC expects rinzimetostat dose optimization data in Q1 2026</p></li><li><p>Company plans to initiate Phase 3 trial for rinzimetostat in 1H 2026</p></li><li><p>ORIC anticipates enozertinib monotherapy data in 2H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Reduced to $25.9 mln from $32 mln due to lower rinzimetostat drug manufacturing costs and lower costs from discontinued programs</p></li><li><p>CASH RUNWAY EXTENSION - Company raised $264 mln, extending cash runway into 2H 2028</p></li></ul><p>Company press release: <span>ID:nGNX4wfBSH</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$30.51 mln</p></td><td></td></tr><tr><td><p>Q4 Income from Operations</p></td><td></td><td><p>-$34.55 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$34.55 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 98% above its February 20 closing price of $11.11</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORIC","symbol_name":"Oric Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ10Y:1","article_id":"2613308057","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613308057","pubTimestamp":1771881483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ORIC Pharmaceuticals Q4 loss narrowsOverviewOncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last yearCompany raised $264 mln, extending cash runway into 2H 2028Significant clinical ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORIC":"Oric Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"ORIC Pharmaceuticals第四季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORIC":0.9},"content_text":"ORIC Pharmaceuticals Q4 loss narrowsOverviewOncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last yearCompany raised $264 mln, extending cash runway into 2H 2028Significant clinical advancements in rinzimetostat and enozertinib reportedOutlookORIC expects rinzimetostat dose optimization data in Q1 2026Company plans to initiate Phase 3 trial for rinzimetostat in 1H 2026ORIC anticipates enozertinib monotherapy data in 2H 2026Result DriversR&D EXPENSES - Reduced to $25.9 mln from $32 mln due to lower rinzimetostat drug manufacturing costs and lower costs from discontinued programsCASH RUNWAY EXTENSION - Company raised $264 mln, extending cash runway into 2H 2028Company press release: ID:nGNX4wfBSHKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Net Income-$30.51 mlnQ4 Income from Operations-$34.55 mlnQ4 Operating Expenses$34.55 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 98% above its February 20 closing price of $11.11For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613308057","isCrawlerRequest":true}